Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Name: Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Published: 2019
License: Public Domain

National Cancer Institute (NCI) · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

locally advanced urothelial carcinoma, metastatic urothelial carcinoma, stage iii bladder cancer ajcc v8, stage iv bladder cancer ajcc v8, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Related documents